Condition: ALSFTD · ALS (Amyotrophic Lateral Sclerosis) · Frontal Temporal Dementia (FTD) · Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)
The aim of this study is to assess the impact of a probiotic formulation on participants with ALS-FTDSD. It is hypothesized that participants given the probiotics will have different lipid profiles compared to participants receiving the placebo at different time points.
This description comes directly from the study's public registry record.
Amélie Bujold, RN · 514-890-8000 · amelie.bujold.chum@ssss.gouv.qc.ca
Richard Miallot, PhD · 514-890-8000 · richard.miallot.chum@ssss.gouv.qc.ca
Always discuss trial participation with your own doctor first.
| Stan Cassidy Centre for Rehabilitation | Fredericton, New Brunswick, Canada | Recruiting |
| Centre Hospitalier de l'Université de Montréal | Montreal, Quebec, Canada | Recruiting |
| University of Saskatchewan, Clinical Trials Support Unit | Saskatoon, Saskatchewan, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06051123